775304-57-9 | 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid

Packsize	Purity	Availability	Price	Discounted Price
5mg	98%	in stock	$6.00	$4.00
10mg	98%	in stock	$8.00	$6.00
50mg	98%	in stock	$10.00	$7.00
100mg	98%	in stock	$12.00	$9.00
250mg	98%	in stock	$18.00	$13.00
1g	98%	in stock	$43.00	$30.00
5g	98%	in stock	$127.00	$89.00
10g	98%	in stock	$190.00	$133.00

Description

• Catalog Number: AC70940
• Chemical Name: 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid
• CAS Number: 775304-57-9
• Molecular Formula: C15H9FN2O3
• Molecular Weight: 284.2420
• MDL Number: MFCD09864996
• SMILES: Fc1ccccc1c1onc(n1)c1cccc(c1)C(=O)O

Computed Properties

• Complexity: 382
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 21
• Hydrogen Bond Acceptor Count: 6
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 3
• XLogP3: 3.1

Literature

• Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression.

  Proceedings of the National Academy of Sciences of the United States of America 20161101

• Proposing a mechanism of action for ataluren.

  Proceedings of the National Academy of Sciences of the United States of America 20161101

• Orphan drug development in muscular dystrophy: update on two large clinical trials of dystrophin rescue therapies.

  Discovery medicine 20131101

• A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays.

  PLoS biology 20130601

• A comparative evaluation of NB30, NB54 and PTC124 in translational read-through efficacy for treatment of an USH1C nonsense mutation.

  EMBO molecular medicine 20121101

• Gene therapy for muscular dystrophy: lessons learned and path forward.

  Neuroscience letters 20121011

• Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy.

  Clinical biochemistry 20121001

• Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy.

  Human molecular genetics 20120915

• Highlights of the North American Cystic Fibrosis Conference 2011.

  Journal of the Royal Society of Medicine 20120601

• Rescue of melanocortin 4 receptor (MC4R) nonsense mutations by aminoglycoside-mediated read-through.

  Obesity (Silver Spring, Md.) 20120501

• Drug treatment of Duchenne muscular dystrophy: available evidence and perspectives.

  Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 20120501

• The chemical compound PTC124 does not affect cellular electrophysiology of cardiac ventricular myocytes.

  Cardiovascular drugs and therapy 20120201

• Personalized medicine comes to cystic fibrosis.

  American journal of medical genetics. Part A 20120201

• Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.

  The Annals of pharmacotherapy 20120101

• Stop codon read-through with PTC124 induces palmitoyl-protein thioesterase-1 activity, reduces thioester load and suppresses apoptosis in cultured cells from INCL patients.

  Molecular genetics and metabolism 20111101

• [Therapeutic readthrough strategy for suppression of nonsense mutations in duchenne muscular dystrophy].

  Brain and nerve = Shinkei kenkyu no shinpo 20111101

• Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis.

  The European respiratory journal 20110701

• PTC124-mediated translational readthrough of a nonsense mutation causing Usher syndrome type 1C.

  Human gene therapy 20110501

• Nonsense suppressor therapies rescue peroxisome lipid metabolism and assembly in cells from patients with specific PEX gene mutations.

  Journal of cellular biochemistry 20110501

• Current status of pharmaceutical and genetic therapeutic approaches to treat DMD.

  Molecular therapy : the journal of the American Society of Gene Therapy 20110501

• PTC124 improves readthrough and increases enzymatic activity of the CPT1A R160X nonsense mutation.

  Journal of inherited metabolic disease 20110401

• Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse.

  PloS one 20110101

• Nonsense-mediated mRNA decay and cystic fibrosis.

  Methods in molecular biology (Clifton, N.J.) 20110101

• Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis.

  American journal of respiratory and critical care medicine 20101115

• Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis.

  Current opinion in pulmonary medicine 20101101

• Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124).

  Journal of child neurology 20100901

• Membrane blebbing as an assessment of functional rescue of dysferlin-deficient human myotubes via nonsense suppression.

  Journal of applied physiology (Bethesda, Md. : 1985) 20100901

• [Research on mRNA degradation and drug discovery].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20100901

• UGA hopping: a sport for nephrologists too?

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20100801

• Molecule of the month. Ataluren.

  Drug news & perspectives 20100301

• Protein biomarkers in cystic fibrosis research: where next?

  Genome medicine 20100101

• Emerging genetic therapies to treat Duchenne muscular dystrophy.

  Current opinion in neurology 20091001

• Emerging treatments in cystic fibrosis.

  Drugs 20091001

• [Mutation-specific treatments for Duchenne muscular dystrophy].

  Brain and nerve = Shinkei kenkyu no shinpo 20090801

• PTC124 for cystic fibrosis.

  Lancet (London, England) 20090425

• Update in cystic fibrosis 2008.

  American journal of respiratory and critical care medicine 20090315

• Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development.

  BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20090101

• Drug developers aim to treat cystic fibrosis through disease modification.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20081215

• New approaches to treatment of primary immunodeficiencies: fixing mutations with chemicals.

  Current opinion in allergy and clinical immunology 20081201

• Introducing sense into nonsense in treatments of human genetic diseases.

  Trends in genetics : TIG 20081101

• Gunvalson decision sends shockwaves through industry.

  Nature biotechnology 20081101

• Reading through premature stop codons with PTC1 24. Project Catalyst to find more Duchenne drugs. Interview by Guenter Scheuerbrandt.

  Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 20081001

• Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial.

  Lancet (London, England) 20080830

• Ignoring the nonsense: a phase II trial in cystic fibrosis.

  Lancet (London, England) 20080830

• Pharmacological probing of type 1 autism.

  Journal of autism and developmental disorders 20080801

• PTC124, nonsense mutations and Duchenne muscular dystrophy.

  Neuromuscular disorders : NMD 20071001

• Studies point way to new therapeutic prospects for muscular dystrophy.

  JAMA 20070926

• PTC124 targets genetic disorders caused by nonsense mutations.

  Nature 20070503

• Chemical biology: ignore the nonsense.

  Nature 20070503

• Emerging drug treatments for cystic fibrosis.

  Expert opinion on emerging drugs 20070501

• Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers.

  Journal of clinical pharmacology 20070401

• Drug evaluation: PTC-124--a potential treatment of cystic fibrosis and Duchenne muscular dystrophy.

  IDrugs : the investigational drugs journal 20061101

• Nonsense mutations: running the red light.

  Nature 20051208